Acute myeloid leukemia (AML) is a rare disease that is seen most often in older adults, although it can occur in younger people as well. This webinar discusses the symptoms of AML, how it is diagnosed, risk factors for developing AML, and current treatment options.

Maintenance therapy after a stem cell transplant is used to decrease early death, increase time to progression and improve the quality of life in patients with multiple myeloma. Dr. Callander provides an overview of the history of maintenance therapy and discusses the new and exciting treatment options available. She also delves into potential future therapies that are currently under study.

A transplant using the patient's own stem cells (an autologous stem cell transplant) or CAR T-cell therapy are treatment options for patients with certain types of lymphoma.

Acute myeloid leukemia is a fast-moving cancer that can be fatal in weeks or months without treatment. This presentation reviews the causes, symptoms, and treatments for AML and recent progress in cure rates or prolonged remission for an increasing number of patients.

Myelodysplastic syndrome (MDS) is a blood disorder that can develop into leukemia. There are several treatments for MDS, including stem cell transplantation. This presentation reviews key features of MDS, treatment options and when a transplant is an appropriate remedy.

Multiple myeloma is a cancer of plasma cells, which are blood cells that are responsible for producing antibodies to fight infections. Patients with multiple myeloma often undergo a stem cell transplant as part of their initial treatment. Maintenance therapy after a stem cell transplant can enable myeloma patients to live longer but can also cause side effects.

Treatment for many cancers now involves maintenance therapy after a remission is achieved. This presentation examines whether maintenance therapy is appropriate for various sub-types of AML after transplant and after some non-transplant therapies.